# Bioequivalence Study of 300 mg Gabapentin

> **NCT01738893** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 26 (actual)

## Conditions studied

- Epilepsy

## Interventions

- **DRUG:** Gabapentin 300 mg
- **DRUG:** Gabapentin 300 mg

## Key facts

- **NCT ID:** NCT01738893
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01-14
- **Primary completion:** 2011-01-22
- **Final completion:** 2011-01-22
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2017-06-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01738893

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01738893, "Bioequivalence Study of 300 mg Gabapentin". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01738893. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*